|
1
|
Gao Y, Wang J, Zhou Y, Sheng S, Qian SY
and Huo X: Evaluation of serum CEA, CA19-9, CA72-4, CA125 and
ferritin as diagnostic markers and factors of clinical parameters
for colorectal cancer. Sci Rep. 8:27322018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang M, Miao F, Huang R, Liu W, Zhao Y,
Jiao T, Lu Y, Wu F, Wang X, Wang H, et al: RHBDD1 promotes
colorectal cancer metastasis through the Wnt signaling pathway and
its downstream target ZEB1. J Exp Clin Cancer Res. 37:222018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mao X, Ou MT, Karuppagounder SS, Kam TI,
Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, et al:
Pathological α-synuclein transmission initiated by binding
lymphocyte-activation gene 3. Science. 353:aah33742016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen N, Liu Y, Guo Y, Chen Y, Liu X and
Liu M: Lymphocyte activation gene 3 negatively regulates the
function of intrahepatic hepatitis C virus-specific CD8+
T cells. J Gastroenterol Hepatol. 30:1788–1795. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hald SM, Rakaee M, Martinez I, Richardsen
E, Al-Saad S, Paulsen EE, Blix ES, Kilvaer T, Andersen S, Busund
LT, et al: LAG-3 in non-small-cell lung cancer: Expression in
primary tumors and metastatic lymph nodes is associated with
improved survival. Clin Lung Cancer. 19:249–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burugu S, Gao D, Leung S, Chia SK and
Nielsen TO: LAG-3+ tumor infiltrating lymphocytes in breast cancer:
Clinical correlates and association with PD-1/PD-L1+ tumors. Ann
Oncol. 28:2977–2984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S, Liechty B, Patel S, Weber JS,
Hollmann TJ, Snuderl M and Karajannis MA: Programmed death ligand 1
expression and tumor infiltrating lymphocytes in neurofibromatosis
type 1 and 2 associated tumors. J Neurooncol. 138:183–190. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gettinger SN, Horn L, Gandhi L, Spigel DR,
Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman
DM, et al: Overall survival and long-term safety of nivolumab
(anti-programmed death 1 antibody, BMS-936558, ONO-4538) in
patients with previously treated advanced non-small-cell lung
cancer. J Clin Oncol. 33:2004–2012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carbognin L, Pilotto S, Milella M, Vaccaro
V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D,
Chilosi M, et al: Differential activity of nivolumab, pembrolizumab
and MPDL3280A according to the tumor expression of programmed
death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma,
lung and genitourinary cancers. PLoS One. 10:e01301422015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Armand P, Shipp MA, Ribrag V, Michot JM,
Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose
S, et al: Programmed death-1 blockade with pembrolizumab in
patients with classical hodgkin lymphoma after brentuximab vedotin
failure. J Clin Oncol. 34:3733–3739. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert C, Ribas A, Wolchok JD, Hodi FS,
Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et
al: Anti-programmed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: A randomised
dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu G, Wang X, Wu S, Li X and Li Q:
Neuroprotective effects of puerarin on
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's
disease model in mice. Phytother Res. 28:179–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lambert E, Fuselier E, Ramont L, Brassart
B, Dukic S, Oudart JB, Dupont-Deshorgue A, Sellier C, Machado C,
Dauchez M, et al: Conformation-dependent binding of a Tetrastatin
peptide to αvβ3 integrin decreases melanoma
progression through FAK/PI3K/Akt pathway inhibition. Sci
Rep. 8:98372018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian J and Yuan L: Sirtuin 6 inhibits
colon cancer progression by modulating PTEN/AKT signaling. Biomed
Pharmacother. 106:109–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Chen H, Wu S, Cheng Y, Li Q, Wang J
and Zhu G: MPP+ inhibits mGluR1/5-mediated long-term
depression in mouse hippocampus by calpain activation. Eur J
Pharmacol. 795:22–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Very N, Lefebvre T and El Yazidi-Belkoura
I: Drug resistance related to aberrant glycosylation in colorectal
cancer. Oncotarget. 9:1380–1402. 2017.PubMed/NCBI
|
|
18
|
Santini FC and Hellmann MD: PD-1/PD-L1
axis in lung cancer. Cancer J. 24:15–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mathew M, Enzler T, Shu CA and Rizvi NA:
Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther.
186:130–137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu S, Chen S, Yuan W, Wang H, Chen K and
Li D and Li D: PD-1/PD-L1 interaction up-regulates MDR1/P-gp
expression in breast cancer cells via PI3K/AKT and MAPK/ERK
pathways. Oncotarget. 8:99901–99912. 2017.PubMed/NCBI
|
|
21
|
Almozyan S, Colak D, Mansour F, Alaiya A,
Al-Harazi O, Qattan A, Al-Mohanna F, Al-Alwan M and Ghebeh H: PD-L1
promotes OCT4 and Nanog expression in breast cancer stem cells by
sustaining PI3K/AKT pathway activation. Int J Cancer.
141:1402–1412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lopez-Rivera E, Jayaraman P, Parikh F,
Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm
EA, Estrada Y, et al: Inducible nitric oxide synthase drives mTOR
pathway activation and proliferation of human melanoma by
reversible nitrosylation of TSC2. Cancer Res. 74:1067–1078. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning
W, Zeng H, Zhang N, Du W, Chen C, et al: PD-L1 induced by IFN-γ
from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT
signaling pathways promoted progression of lung cancer. Int J Clin
Oncol. 22:1026–1033. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blank C, Brown I, Peterson AC, Spiotto M,
Iwai Y, Honjo T and Gajewski TF: PD-L1/B7H-1 inhibits the effector
phase of tumor rejection by T cell receptor (TCR) transgenic
CD8+ T cells. Cancer Res. 64:1140–1145. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen LT and Ohashi PS: Clinical blockade
of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol.
15:45–56. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu G, Wang X, Wu S and Li Q: Involvement
of activation of PI3K/Akt pathway in the protective effects of
puerarin against MPP+-induced human neuroblastoma
SH-SY5Y cell death. Neurochem Int. 60:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maugeri G, D'Amico AG, Rasà DM, Saccone S,
Federico C, Magro G, Cavallaro S and D'Agata V: Caffeine inhibits
angiogenesis in human glioblastoma cells via HIFs modulation.
Anticancer Agents Med Chem. Feb 9–2018.(Epub ahead of print). doi:
10.2174/1871520618666180209151750. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Yang S and Zhu G: Postnatal calpain
inhibition elicits cerebellar cell death and motor dysfunction.
Oncotarget. 8:87997–88007. 2017.PubMed/NCBI
|
|
31
|
Suh DS, Park SE, Jin H, Lee K and Bae J:
LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial
adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated
apoptosis and cell-cycle. Oncogenesis. 7:32018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen L, Xiong YQ, Xu J, Wang JP, Meng ZL
and Hong YQ: Juglanin inhibits lung cancer by regulation of
apoptosis, ROS and autophagy induction. Oncotarget. 8:93878–93898.
2017.PubMed/NCBI
|
|
33
|
Okamura T, Fujio K, Shibuya M, Sumitomo S,
Shoda H, Sakaguchi S and Yamamoto K:
CD4+CD25−LAG3+ regulatory T cells
controlled by the transcription factor Egr-2. Proc Natl Acad Sci
USA. 106:13974–13979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okamura T, Sumitomo S, Morita K, Iwasaki
Y, Inoue M, Nakachi S, Komai T, Shoda H, Miyazaki J, Fujio K and
Yamamoto K: TGF-β3-expressing
CD4+CD25−LAG3+ regulatory T cells
control humoral immune responses. Nat Commun. 6:63292015.
View Article : Google Scholar : PubMed/NCBI
|
